Recombinant Rat MAPK3 Protein

• Cat.No.: MAPK3-3574R
• Product Overview: Recombinant Rat MAPK3 full length or partial length protein was expressed.

Specification

• Source: Mammalian Cells
• Species: Rat
• Tag: His
• Form: Liquid or lyophilized powder
• Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.
• Purity: >80%
• Notes: This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications.
• Storage: Store it at +4 ºC for short term. For long term storage, store it at -20 ºC~-80 ºC.
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: Mapk3 mitogen activated protein kinase 3 [ Rattus norvegicus ]
• Official Symbol: MAPK3
• Gene ID: 50689
• mRNA Refseq: NM_017347.2
• Protein Refseq: NP_059043.1
• UniProt ID: P21708

Reviews

12/29/2021

Exemplary precision and unblemished dependability render it my most cherished research ally.

01/20/2021

Presenting exceptional reliability and stability, the experimental reagent establishes a robust foundation for my experiments.

11/14/2019

Exquisitely crafted packaging design adds convenience to the usage of this protein reagent and exudes a sense of sophistication.

Q&As

How is MAPK3 involved in disease development?

Dysregulation of MAPK3 signaling has been implicated in the pathogenesis of several diseases. Aberrant activation of MAPK3 is associated with cancer development and progression, as it promotes cell proliferation and survival. MAPK3 signaling is also involved in cardiovascular diseases, contributing to vascular remodeling and hypertrophy. In neurodegenerative diseases, dysregulated MAPK3 activity contributes to neuronal dysfunction and apoptosis.

What are the future directions in MAPK3 research?

Future research in MAPK3 aims to elucidate the intricate signaling network and identify novel regulatory mechanisms. Understanding the crosstalk between MAPK3 and other signaling pathways will be crucial for developing targeted therapies. Additionally, exploring the role of MAPK3 isoforms in different cellular contexts and disease states will provide valuable insights. Furthermore, the development of more specific and potent inhibitors with reduced toxicity profiles is a focus for future therapeutic interventions.

What is the molecular structure and function of MAPK3 protein?

MAPK3, also known as ERK1 (Extracellular Signal-Regulated Kinase 1), is a serine/threonine kinase involved in cell signaling pathways. It consists of 379 amino acids and exhibits a conserved catalytic domain. MAPK3 plays a crucial role in regulating cell proliferation, differentiation, and survival by phosphorylating downstream targets such as transcription factors and other kinases.

What are the downstream effectors of MAPK3 signaling?

MAPK3 signaling exerts its effects through phosphorylation of downstream targets. It phosphorylates various transcription factors, including ELK1 and c-Fos, leading to changes in gene expression. MAPK3 also phosphorylates other kinases, such as p90RSK, which further propagate the signal to regulate cellular processes like cell cycle progression, apoptosis, and differentiation.

What are the current challenges in targeting MAPK3 for therapy?

One challenge is the potential for off-target effects when targeting MAPK3, as it is involved in multiple signaling pathways. Additionally, resistance to MAPK3 inhibitors can emerge due to compensatory signaling mechanisms and genetic alterations. Another challenge lies in achieving selective inhibition of specific MAPK3 isoforms without affecting other closely related kinases.

How is the activity of MAPK3 regulated?

The activity of MAPK3 is tightly regulated by various mechanisms. Activation of MAPK3 involves dual phosphorylation of threonine and tyrosine residues by upstream kinases. Conversely, dephosphorylation by phosphatases can inactivate MAPK3. Additionally, scaffolding proteins and interacting partners can modulate its activity by facilitating or inhibiting its phosphorylation or by regulating its subcellular localization.

What therapeutic strategies target MAPK3?

Inhibition of MAPK3 activity or downstream effectors represents a potential therapeutic approach. Small molecule inhibitors targeting MAPK3 kinase activity, such as U0126 and PD98059, have been developed. Monoclonal antibodies against MAPK3 or its downstream effectors are also being investigated. Combination therapies targeting multiple components of the MAPK3 signaling pathway are being explored to enhance efficacy and overcome resistance.